Published online May 7, 2017. doi: 10.3748/wjg.v23.i17.3043
Peer-review started: November 3, 2016
First decision: December 19, 2016
Revised: January 11, 2017
Accepted: February 8, 2017
Article in press: February 8, 2017
Published online: May 7, 2017
Processing time: 186 Days and 1.7 Hours
Macrophage inflammatory protein (MIP)-2 is one of the CXC chemokines and is also known as chemokine CXC ligand (CXCL2). MIP-2 affects neutrophil recruitment and activation through the p38 mitogen-activated-protein-kinase-dependent signaling pathway, by binding to its specific receptors, CXCR1 and CXCR2. MIP-2 is produced by a variety of cell types, such as macrophages, monocytes, epithelial cells, and hepatocytes, in response to infection or injury. In liver injury, activated Kupffer cells are known as the major source of MIP-2. MIP-2-recruited and activated neutrophils can accelerate liver inflammation by releasing various inflammatory mediators. Here, we give a brief introduction to the basic molecular and cellular sources of MIP-2, and focus on its physiological and pathological functions in acute liver injury induced by concanavalin A, lipopolysaccharides, irradiation, ischemia/reperfusion, alcohol, and hypoxia, and hepatectomy-induced liver regeneration and tumor colorectal metastasis. Further understanding of the regulatory mechanisms of MIP-2 secretion and activation may be helpful to develop MIP-2-targeted therapeutic strategies to prevent liver inflammation.
Core tip: Macrophage inflammatory protein (MIP)-2 is produced by a variety of cell types in response to infection or injury, and affects neutrophil recruitment and activation by binding to chemokine CXC receptor (CXCR)1 and CXCR2. MIP-2 plays a complex dual role in the development of liver diseases by mediating liver inflammation at a high concentration and promoting liver regeneration at a low concentration. Here, we review its physiological and pathological functions in various types of liver damage. Further understanding of the regulatory mechanisms of MIP-2 may be helpful to develop MIP-2-targeted therapeutic strategies.